SPI-62

DRUG4 trials

Sponsors

Sparrow Pharmaceuticals

Conditions

Cortisol ExcessCortisol OverproductionCortisol; HypersecretionCushing Disease Due to Increased ACTH SecretionCushing's Syndrome IEctopic ACTH SecretionObesityPolymyalgia Rheumatica

Phase 1

A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62

CompletedNCT05409027

Sparrow PharmaceuticalsObesity, Type2Diabetes, Type 2 Diabetes Mellitus in Obese

Start: 2021-07-23End: 2024-02-07Updated: 2024-04-22

A Trial of Prednisolone in Combination With SPI-62 in Participants With Polymyalgia Rheumatica (PMR)

TerminatedNCT06281236

Sparrow PharmaceuticalsPolymyalgia Rheumatica

Start: 2022-02-22End: 2025-04-25Updated: 2025-05-16

Phase 2

SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

CompletedNCT05307328

Sparrow PharmaceuticalsCortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction +3

Start: 2022-09-01End: 2025-08-01Updated: 2025-10-08

A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR)

CompletedNCT05436652

Sparrow PharmaceuticalsPolymyalgia Rheumatica

Start: 2022-07-22End: 2025-04-25Updated: 2025-05-11